2. Peptides
  3. Peptide and Derivatives
  4. Inhibitors and Substrates

Inhibitors and Substrates

Custom Peptide Synthesis

In a broader sense, peptide inhibitors refer to peptides that specifically bind to the active sites of target enzymes or receptors to modulate their functions. Depending on their regulatory effects, they can act as inhibitors, agonists, or antagonists, providing powerful tools for disease research and therapeutic development.
Substrate peptides, on the other hand, can be specifically recognized and catalyzed by the active sites of target enzymes, making them valuable reporters for monitoring enzyme activities.

 

Inhibitors and Substrates (3595):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13948
    Angiotensin II human 4474-91-3 99.98%
    Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
    Angiotensin II human
  • HY-114118
    Semaglutide 910463-68-2 99.74%
    Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
    Semaglutide
  • HY-P1410
    GsMTx4 1209500-46-8 99.89%
    GsMTx4 is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology.
    GsMTx4
  • HY-A0190
    Caerulein 17650-98-5 99.96%
    Caerulein is a decapeptide and a potent cholecystokinin receptor agonist. Caerulein is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.
    Caerulein
  • HY-P0175
    740 Y-P 1236188-16-1 99.67%
    740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone.
    740 Y-P
  • HY-P11474
    FZ1 peptide 99.92%
    FZ1 peptide is an integrin αvβ3 agonist. FZ1 peptide binds to integrin αvβ3, effectively activates FAK, FAK-dependent AKT and ERK1/2 signaling pathways. FZ1 peptide enhances VEGFC-induced endothelial angiogenesis, accelerates diabetic skin wound healing.
    FZ1 peptide
  • HY-P10118A
    Cathepsin L-IN-3 TFA 98.18%
    Cathepsin L-IN-3 (Compound cat L inh. 7) TFA is selective a noncovalent cathepsin L inhibitor with a Ki of 4.3 nM.
    Cathepsin L-IN-3 TFA
  • HY-P5450A
    PDKtide TFA 99.07%
    PDKtide TFA, a biological active peptide, is a substrate for phosphatidylinositide-dependent kinase 1 (PDK1).
    PDKtide TFA
  • HY-13443
    Exendin-4 141758-74-9 99.89%
    Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
    Exendin-4
  • HY-P1156
    Insulin(cattle) 11070-73-8
    Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.
    Insulin(cattle)
  • HY-P0018
    Pepstatin 26305-03-3 99.90%
    Pepstatin (Pepstatin A) is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin also inhibits HIV protease.
    Pepstatin
  • HY-P0252
    α-MSH 581-05-5 99.98%
    α-MSH (α-Melanocyte-Stimulating Hormone), an endogenous neuropeptide, is an endogenous melanocortin receptor 4 (MC4R) agonist with anti-inflammatory and antipyretic activities. α-MSH is a post-translational derivative of pro-opiomelanocortin (POMC).
    α-MSH
  • HY-P0201
    Substance P 33507-63-0 99.60%
    Substance P (Neurokinin P) is a CNS-penetrant neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).
    Substance P
  • HY-P0014
    Liraglutide 204656-20-2 99.95%
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
    Liraglutide
  • HY-P3506
    Retatrutide 2381089-83-2 99.96%
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
    Retatrutide
  • HY-P0264
    Exendin(9-39) amide 133514-43-9 99.81%
    Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH).
    Exendin(9-39) amide
  • HY-P1097
    Gastrin I, human 10047-33-3 99.93%
    Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.
    Gastrin I, human
  • HY-101297
    Z-IETD-FMK 210344-98-2 98.0%
    Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell permeable caspase-8 inhibitor. Z-IETD-FMK is also a granzyme B inhibitor.
    Z-IETD-FMK
  • HY-P3462
    Cagrilintide 1415456-99-3 99.97%
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.
    Cagrilintide
  • HY-P0224
    N-Formyl-Met-Leu-Phe 59880-97-6 99.90%
    N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.
    N-Formyl-Met-Leu-Phe